Feng Chi Biotech Corp.(TW:6744)
NT$12.900.00 (0.00%)
TW:6744
Feng Chi Biotech Corp. financials statements
NT$12.90
At close:0.00 (0.00%)
Feng Chi Biotech Corp. (6744) Ratios
Feng Chi Biotech Corp. Ratios
TW:6744's free cash flow for Q2 2026 was NT$-2.75M. For the 2026 fiscal year, TW:6744's free cash flow was decreased by NT$-258.00K and operating cash flow was NT$-2.49M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.14 | 4.60 | 4.66 | 4.47 | 4.74 |
| Quick Ratio | 4.38 | 4.24 | 4.31 | 4.06 | 4.37 |
| Cash Ratio | 0.38 | 0.49 | 0.56 | 1.07 | 0.87 |
| Solvency Ratio | 0.55 | 0.44 | 0.48 | 0.43 | 0.57 |
| Operating Cash Flow Ratio | 0.07 | 0.47 | 0.28 | 0.46 | 0.59 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 263.81 | 0.00 |
| Net Current Asset Value | NT$ 184.58M | NT$ 187.13M | NT$ 192.17M | NT$ 202.73M | NT$ 209.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.04 | 0.04 | 0.01 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.05 | 0.06 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.04 | 0.05 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.20 | 1.25 | 1.26 | 1.31 | 1.24 |
| Debt Service Coverage Ratio | 129.90 | 102.62 | 93.33 | 186.64 | 326.88 |
| Interest Coverage Ratio | 76.50 | 63.48 | 74.34 | 466.66 | 269.81 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.36 | 0.55 | 0.72 | 0.88 | 0.17 |
| Net Debt to EBITDA | -0.46 | -0.61 | -0.57 | -1.42 | -1.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 44.63% | 45.09% | 44.08% | 43.13% | 47.16% |
| EBIT Margin | 7.81% | 12.03% | 15.30% | 15.75% | 15.42% |
| EBITDA Margin | 14.64% | 17.42% | 19.29% | 19.02% | 20.24% |
| Operating Profit Margin | 7.81% | 9.42% | 13.38% | 13.99% | 14.48% |
| Pretax Profit Margin | 9.55% | 11.88% | 15.12% | 15.72% | 15.37% |
| Net Profit Margin | 8.16% | 9.70% | 12.62% | 12.72% | 12.67% |
| Continuous Operations Profit Margin | 8.16% | 9.70% | 12.62% | 12.72% | 12.67% |
| Net Income Per EBT | 85.48% | 81.61% | 83.49% | 80.92% | 82.45% |
| EBT Per EBIT | 122.29% | 126.12% | 112.98% | 112.39% | 106.12% |
| Return on Assets (ROA) | 5.03% | 5.55% | 7.57% | 7.98% | 8.07% |
| Return on Equity (ROE) | 6.03% | 6.92% | 9.58% | 10.44% | 10.04% |
| Return on Capital Employed (ROCE) | 5.71% | 6.57% | 9.81% | 10.97% | 11.47% |
| Return on Invested Capital (ROIC) | 4.82% | 5.30% | 8.11% | 8.78% | 9.35% |
| Return on Tangible Assets | 5.03% | 5.55% | 7.57% | 7.99% | 8.07% |
| Earnings Yield | 5.28% | 5.44% | 6.45% | 8.00% | 6.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.57 | 10.74 | 12.10 | 16.77 | 14.48 |
| Payables Turnover | 6.90 | 5.50 | 7.80 | 5.89 | 6.47 |
| Inventory Turnover | 2.83 | 4.93 | 5.30 | 4.32 | 4.75 |
| Fixed Asset Turnover | 5.39 | 5.26 | 6.63 | 7.96 | 13.60 |
| Asset Turnover | 0.62 | 0.57 | 0.60 | 0.63 | 0.64 |
| Working Capital Turnover Ratio | 0.93 | 0.87 | 0.87 | 0.91 | 0.88 |
| Cash Conversion Cycle | 107.70 | 41.65 | 52.18 | 44.29 | 45.73 |
| Days of Sales Outstanding | 31.55 | 33.97 | 30.16 | 21.77 | 25.20 |
| Days of Inventory Outstanding | 129.08 | 73.99 | 68.81 | 84.48 | 76.92 |
| Days of Payables Outstanding | 52.93 | 66.31 | 46.78 | 61.96 | 56.39 |
| Operating Cycle | 160.63 | 107.96 | 98.97 | 106.25 | 102.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.21 | 1.63 | 1.00 | 1.85 | 2.14 |
| Free Cash Flow Per Share | -0.64 | 0.68 | 0.91 | 1.84 | 2.07 |
| Dividend Paid and CapEx Coverage Ratio | 0.12 | 0.81 | 0.69 | 1.46 | 1.75 |
| Capital Expenditure Coverage Ratio | 0.25 | 1.72 | 11.05 | 109.58 | 30.07 |
| Operating Cash Flow Coverage Ratio | 0.60 | 3.07 | 1.43 | 2.11 | 12.91 |
| Operating Cash Flow to Sales Ratio | 0.02 | 0.15 | 0.09 | 0.15 | 0.18 |
| Free Cash Flow Yield | -3.61% | 3.43% | 3.97% | 9.18% | 8.35% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 18.94 | 18.33 | 15.51 | 12.50 | 16.50 |
| Price-to-Sales (P/S) Ratio | 1.55 | 1.78 | 1.96 | 1.59 | 2.09 |
| Price-to-Book (P/B) Ratio | 1.14 | 1.27 | 1.49 | 1.30 | 1.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -27.72 | 29.16 | 25.21 | 10.90 | 11.97 |
| Price-to-Operating Cash Flow Ratio | 84.71 | 12.17 | 22.93 | 10.80 | 11.58 |
| Price-to-Earnings Growth (PEG) Ratio | -1.46 | -0.68 | -2.07 | 1.88 | -1.82 |
| Enterprise Value Multiple | 10.09 | 9.62 | 9.58 | 6.94 | 9.06 |
| Enterprise Value | 262.16M | 286.82M | 333.62M | 255.25M | 334.89M |
| EV to EBITDA | 10.09 | 9.62 | 9.58 | 6.94 | 9.06 |
| EV to Sales | 1.48 | 1.68 | 1.85 | 1.32 | 1.83 |
| EV to Free Cash Flow | -26.51 | 27.43 | 23.80 | 9.04 | 10.52 |
| EV to Operating Cash Flow | 81.01 | 11.45 | 21.64 | 8.96 | 10.17 |
| Tangible Book Value Per Share | 15.57 | 15.58 | 15.45 | 15.32 | 14.97 |
| Shareholders’ Equity Per Share | 15.58 | 15.58 | 15.45 | 15.33 | 14.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.18 | 0.17 | 0.19 | 0.18 |
| Revenue Per Share | 11.52 | 11.11 | 11.73 | 12.58 | 11.86 |
| Net Income Per Share | 0.94 | 1.08 | 1.48 | 1.60 | 1.50 |
| Tax Burden | 0.85 | 0.82 | 0.83 | 0.81 | 0.82 |
| Interest Burden | 1.22 | 0.99 | 0.99 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.08 | 0.09 | 0.07 | 0.06 | 0.08 |
| SG&A to Revenue | 0.29 | 0.27 | 0.24 | 0.23 | 0.25 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.19 | 1.23 | 0.68 | 1.16 | 1.42 |
Currency in TWD
